Abbott India Limited Overview
Abbott India Limited is the listed Indian pharmaceutical subsidiary of Abbott Laboratories and one of the most profitable multinational pharma franchises in the Indian Pharmaceutical Market (IPM). It markets a branded-generics portfolio of roughly 140+ brands concentrated in gastroenterology, women's health, metabolics (thyroid and diabetes), central nervous system (vertigo, sleep, depression), multi-specialty (vitamin D, pain) and vaccines, and it also earns distribution margins on in-licensed brands from Novo Nordisk (insulins, oral and injectable semaglutide) and Abbott Healthcare Pvt Ltd. Its moat rests on category-leading heritage brands — Thyronorm, Udiliv, Duphalac, Cremaffin, Digene, Duphaston, Vertin, Creon, Influvac — that hold #1 or #2 positions in their sub-segments, a highly productive field force, an asset-light manufacturing model (one owned plant in Goa plus third-party manufacturing), zero financial debt and a ~90% dividend payout. FY2026 revenue was ₹6,929 Cr with a 22.4% net margin and ~34.5% return on average equity.
Company's own description (paraphrased from Annual Report FY2025-26)
The Annual Report describes Abbott India as a company that has been advancing health in India for more than eight decades by combining Abbott's global scientific expertise with trusted brands and local market understanding. It names its core therapy areas as Gastrointestinal, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty, and describes its strategy as expanding into differentiated therapies and preventive healthcare, executed through a digitally enabled sales organisation, deep physician/specialist relationships and operational excellence. The investment-case page frames the "next phase of growth" around expanding access in high-burden, under-penetrated therapy areas (cardiometabolic, liver disease including MASLD/MASH, CNS and adult immunisation), building integrated multi-franchise platforms across the continuum of care, and pursuing a "build and partner" approach that combines organic brand building with selective partnerships and acquisitions.
Independent characterisation
Abbott India is, economically, a brand-owning marketing and distribution company with light manufacturing. Its value creation lies in (a) owning or exclusively commercialising prescription brands that physicians habitually prescribe, (b) a large, trained medical-representative ("Therapy Business Manager") force that details ~250,000 healthcare professionals (≈13,000 CME programmes in FY2026), and (c) a supply chain that leans on third-party and affiliate manufacturing, with its single owned plant at Goa producing tablets and liquids (FY2026 incremental production: 1,338.72 MT tablets; 7,311.91 kL liquids).
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales (branded formulations); no subscription or material licensing revenue disclosed |
| Own brands vs in-licensed | Own/Abbott-group brands form the core; a material layer of revenue comes from distributing Novo Nordisk products (Human Mixtard, Novomix, Ryzodeg, Rybelsus; Extensior from 2026; Awiqli from mid-2026) and certain Abbott Healthcare Pvt Ltd brands on which Abbott India earns a distribution margin. Exact split not publicly disclosed |
| Value-chain position | Downstream: brand ownership, medical promotion, regulatory, distribution. Limited upstream manufacturing (Goa) |
| Customers (direct) | Independent distributors / stockists; institutional channels (corporate hospitals, specialty networks) being expanded |
| Customers (demand drivers) | Physicians (gastroenterologists, gynaecologists, endocrinologists/diabetologists, consulting physicians, ENT/neurologists, orthopaedics) and, for OTC-adjacent brands (Digene), consumers |
| End-markets | Indian domestic prescription market (IPM) overwhelmingly; a small international business is housed under the Women's Health/Metabolics commercial director |
| Pricing environment | Regulated: a subset of products falls under the Drug Price Control Order / National List of Essential Medicines (NPPA ceilings); non-scheduled products limited to ~10% annual price increases |
| Channel | Products are sold through independent distributors primarily within India (company description in filings) |
End-markets served (therapy lens)
Per Pharmarack MAT July 2026 data cited by BOB Capital Markets (3 Sept 2026), Abbott India's secondary-market sales were ≈₹5,000 Cr (+10% YoY), of which gastro ≈46% (≈₹2,300 Cr) and women's health ≈10% (≈₹492 Cr, +8%). Note that secondary-market (retail audit) values differ from reported revenue (which is net of trade margins and includes distribution arrangements).
Strategy
Stated strategy (paraphrased themes, AR FY2025-26)
-
Sustained market-beating growth in therapy areas and brands with durable demand.
-
Building and sustaining large brands valued by physicians and patients.
-
Therapy-area relevance: chronic/sub-chronic care, preventive health and adult vaccination, metabolic disorders, women's health, GI/liver and CNS.
-
Productivity and profitability: balance growth investment with cost discipline and sustainable margin thresholds.
-
Build and partner: organic development and lifecycle management plus selective partnerships and potential acquisitions to enter adjacencies.
-
Go-to-market evolution: institutional channels, corporate hospitals, specialty networks; digital and analytics; Tier 2/3 expansion.
-
People: internal succession (all leadership appointments in FY2026 filled internally; attrition declined).
The MD's letter sets an aspiration of "market-aligned growth" with continued profitability improvement; the business model page lists five Abbott-wide sustainability priorities (healthy environment; innovation for access and affordability; diverse workforce; resilient supply chain; responsible use of data and technology).
Strategic initiatives — last 24 months
| Date | Initiative | Type | Detail / intent |
|---|---|---|---|
| Jun 2025 | Leadership transition to Kartik Rajendran | Leadership | Specialty-care and SE Asia commercial background |
| FY2026 | Field-force build-out (345+ TBMs onboarded; 150,000+ person-hours of frontline training) | Capability | Supports GLP-1 and new launches |
| FY2026 | Five new product launches incl. Duphalac Rapid, Combinorm Plus, Digene Insta On The Go | Lifecycle | Leverage brand equity |
| FY2026 | SKU rationalisation in Multi-Specialty | Cost/portfolio | Improve productivity |
| FY2026 | Vaccine sourcing/supply-chain streamlining | Operations | Peak-season reliability |
| 27 Feb 2026 | Extensior (semaglutide) with Novo Nordisk India | Partnership | GLP-1 entry beyond Novo's own reach |
| Jul–Aug 2026 | Awiqli once-weekly insulin distribution | Partnership | Partially offsets Mixtard phase-out |
| FY2026–27 | Women's Health diversification into fertility, contraception, menopause | Portfolio | Reduce dydrogesterone dependence |
| FY2026–27 | Adult immunisation expansion beyond metros | Market access | Under-penetrated category |
| FY2026 | ~90% payout incl. ₹131 special dividend | Capital allocation | Return surplus cash |
| Ongoing | CSR: PHC upgrades (209 cumulative), NCD-nutrition programme design | ESG | Access to care |
Cost programmes with targets: none with quantified targets disclosed. Medium-term financial targets/guidance: none disclosed; management targets market-aligned growth and margin resilience.
Products & Services
Abbott India markets 140+ brands (ICICI Securities). Seven brands are in the IPM top 100 and ten in the top 300 (IQVIA MAT March 2026, per AR). Pricing is regulated or MRP-based; individual brand MRPs are not tabulated by the company.
Gastrointestinal
| Brand | Molecule / description | Indication | Target prescriber | Status / data points |
|---|---|---|---|---|
| Udiliv | Ursodeoxycholic acid | Cholestatic liver disease, gallstones, hepatoprotection | Gastroenterologists, physicians | #1 hepatoprotective brand; crossed ₹700 Cr (AR FY2026); MAT ≈₹712 Cr, ~52% market share (ICICI/BOB 2025) |
| Duphalac | Lactulose | Constipation, hepatic encephalopathy | Physicians, gastroenterologists | Top-10 brand; Duphalac Rapid launched FY2026 |
| Cremaffin / Cremaffin Plus | Liquid paraffin + milk of magnesia (+ sodium picosulfate in Plus) | Constipation | Physicians | Leadership in laxatives |
| Digene | Antacid/antiflatulent (multiple formats) | Acidity, gas | Consumers, physicians | #ControlKar campaign reached 44 million consumers; brand awareness 96%; Digene Insta On The Go (tear-and-sip; orange flavour launched FY2026) won two Gold and one Silver at afaqs! Digies |
| Creon | Pancrelipase (pancreatin) | Exocrine pancreatic insufficiency | Gastroenterologists | Global Abbott brand under further development (AR) |
| Ganaton | Itopride | Functional dyspepsia / GI motility | Physicians, gastroenterologists | Crossed ₹100 Cr in FY2026 |
| Colospa | Mebeverine | Irritable bowel syndrome | Gastroenterologists | Ranks in top of respective market (AR) |
| Librax | Chlordiazepoxide + clidinium | IBS | Gastroenterologists | Top brand in RPM (AR) |
| Heptral | Ademetionine | Liver disease | Hepatologists | Listed among top brands (AR) |
| Pankreoflat | Pancreatin + dimethicone | Indigestion/flatulence | Physicians | Legacy brand |
| Vonefi | Launch FY2026 | Acid-related disorders (GI) | Gastroenterologists | New launch |
| Digeraft | Launch FY2026 | GI (antacid/reflux segment) | Physicians | Listed among top brands in RPM |
Metabolics (own and in-licensed)
| Brand | Molecule / description | Indication | Ownership | Data points |
|---|---|---|---|---|
| Thyronorm | Levothyroxine sodium (multiple strengths) | Hypothyroidism | Own | #1 in hormones; MAT ≈₹716 Cr; ~55.6% share (ICICI/BOB); #LiveThyronormal awareness campaign |
| Combinorm Plus | Launch FY2026 | Metabolic | Own | New launch |
| Extensior | Semaglutide injection (second brand of Ozempic), manufactured by Novo Nordisk | Type 2 diabetes (adjunct to diet/exercise) | Exclusive commercialisation for Novo Nordisk India (Feb 2026) | Pricing not publicly disclosed |
| Human Mixtard | Premixed human insulin | Diabetes | Novo Nordisk (distributed) | ≈₹795 Cr MAT Jan 2026, #5 brand in IPM (Pharmarack); being phased out by Novo |
| Novomix | Biphasic insulin aspart | Diabetes | Novo Nordisk (distributed) | Declined in Q3 FY2026 (ICICI) |
| Ryzodeg | Insulin degludec + insulin aspart | Diabetes | Novo Nordisk (distributed) | Growing; improved IPM rank in May 2026 (Equirus) |
| Rybelsus | Oral semaglutide | Type 2 diabetes | Novo Nordisk (distributed) | ≈₹400 Cr MAT May 2025, 173% 3-year CAGR (BOB, July 2025) |
| Awiqli | Insulin icodec, once-weekly basal insulin | Type 1 and Type 2 diabetes | Novo Nordisk (Abbott distribution confirmed Aug 2026) | ₹261/week for 70 units; 1 mL pen (700 units) MRP ₹2,611; 3 mL pen ₹7,833 |
Women's Health
| Brand | Molecule | Indication | Data points |
|---|---|---|---|
| Duphaston | Dydrogesterone | Threatened/recurrent miscarriage, luteal support in IVF, progesterone deficiency | Category leader; "She Deserves Duphaston" campaign; ESHRE-guideline-aligned programme; facing lower-priced generics |
| Femoston | Estradiol + dydrogesterone | Menopausal hormone therapy | "Fearless Tomorrow" menopause awareness |
| Duvadilan | Isoxsuprine | Pre-term labour | Top brand in RPM |
| Femilon | Desogestrel + ethinylestradiol | Contraception | +3% / +14% in recent periods (BOB table) |
| Novelon | Desogestrel + ethinylestradiol | Contraception | — |
Central Nervous System
| Brand | Molecule | Indication | Data points |
|---|---|---|---|
| Vertin | Betahistine | Vertigo (incl. BPPV, Ménière's) | ≈₹396 Cr MAT Jan 2026, +18.1% value growth (Pharmarack) |
| Prothiaden | Dothiepin (dosulepin) | Depression, pain | Top brand in RPM |
| Inderal | Propranolol | Migraine prophylaxis, anxiety, hypertension | Legacy brand |
| Zolfresh | Zolpidem | Insomnia | Top brand in RPM |
| Eptoin | Phenytoin | Epilepsy | Legacy brand (company fact sheet) |
Multi-Specialty
| Brand | Molecule | Indication | Data points |
|---|---|---|---|
| Arachitol / Arachitol Nano | Cholecalciferol (vitamin D3), nano-formulation | Vitamin D deficiency | Driver of segment growth; D-STRONG ACTIVE LIFE screened 70,000+ individuals |
| Arachitol Injection | Cholecalciferol injection | Vitamin D deficiency | — |
| Brufen / Brufen P | Ibuprofen; ibuprofen + paracetamol | Pain, fever | Legacy brand |
| Ezybixy | Launch FY2026 (therapy/composition not disclosed in sources reviewed) | — | New launch |
Vaccines
| Brand | Description | Indication | Data points |
|---|---|---|---|
| Influvac | Inactivated influenza vaccine (manufactured by Abbott group) | Influenza prevention (adult, maternal, paediatric) | Among IPM top-50 brands; FOGSI partnership for antenatal flu vaccination |
| Pneumoshield 14 | 14-valent pneumococcal vaccine | Pneumococcal disease | Supported by Pneumoserve long-term study |
| Havshield | Hepatitis A vaccine | Hepatitis A | — |
| Typhoid and Japanese encephalitis vaccines | Brands not named in sources reviewed | — | Part of preventive portfolio |
FY2026 new launches (AR)
Duphalac Rapid; Extensior; Ezybixy; Combinorm Plus; Digene Insta On The Go (Orange). Additional GI launches discussed: Vonefi, Digeraft. Five "new products launched" are counted in AR outputs. Company track record: >100 product launches over 12 years (ICICI Securities); 7 new brands in FY2025 (incl. Citrosoda UTI).
Services
No paid services. "Beyond the pill" patient-support and screening programmes (thyroid, liver, vitamin D screening; 14.08 lakh screenings via health clinics in CSR programmes) support brand franchises but are not monetised.
Financial Narrative
All figures standalone Ind AS, ₹ Cr, fiscal years ending 31 March. Source: Annual Report FY2025-26 (10-year highlights) unless noted. Abbott India has no subsidiaries; standalone = company.
Income statement
FY2021 base for CAGR: revenue ₹4,310 Cr; PAT ₹691 Cr.
Margins and growth
CAGRs (computed): Revenue FY2021–26 (5-year) 9.9%; FY2022–26 (4-year) 9.0%. PAT FY2022–26 18.1%. EBITDA (incl. OI) FY2022–26 16.9%. The Annual Report states 10-year CAGRs of 9.0% (revenue), 17.0% (EBITDA), 18.8% (PAT) and 18.8% (share price).
Commentary. The defining feature of the last five years is margin expansion outpacing a high-single-digit top line. Revenue compounded at ~9%, broadly in line with the IPM, while PAT compounded at ~18%. Three drivers stand out. First, operating leverage on fixed costs: employee expense was virtually flat from FY2022 (₹579 Cr) to FY2025 (₹588 Cr) while revenue rose 30%, and other expenses rose only ~6% over the same period. Second, mix: own high-margin brands (Udiliv, Thyronorm, Cremaffin, Vertin) outgrew the low-margin distributed insulin portfolio, lifting gross margin to 46.7% in FY2026. Third, other income tripled from ₹83 Cr to ₹288 Cr as the cash pile grew and yields rose; other income was ~14% of PBT in FY2026.
FY2026 shows an inflection in cost growth: employee cost jumped 13.8% (₹588 Cr → ₹669 Cr), reflecting the Labour Code accrual (₹18.10 Cr), field-force additions (345+ new TBMs onboarded) and, per BOB Capital (Feb 2026), preparation for the GLP-1 launch. Finance cost more than doubled to ₹25 Cr due to Ind AS 116 lease accounting (likely the new BKC corporate office lease — inference), cutting interest coverage from 166x to 84x, though this is non-economic for a debt-free company. Revenue growth slowed to 8.1%, below the IPM's ~8–10% in CY2025–26, which brokers attribute to the Novo Mixtard phase-out (BOB, May 2026).
Quarterly trajectory
Q3 FY2026 revenue and PAT are computed as balancing figures (full year less other quarters); Q3/Q4 EPS computed on 21,249,302 shares. Q1 FY2027: revenue +4.3% YoY, PBT ₹572.21 Cr (+16.0%), PAT +17.1%, EBITDA margin 28.81% vs 25.63% (company results; margin per results commentary). Total income ₹1,889.05 Cr; total expenses ₹1,316.84 Cr. Q4 FY2026: revenue +6.5%, PAT +7.6%, operating profit +12.2% to ₹480.85 Cr.
Q2 FY2027 (quarter ended 30 Sep 2026) results are pending; trading window closed from 1 Oct 2026; statutory deadline 14 Nov 2026; board-meeting date not yet disclosed in sources reviewed.
Balance sheet
Sources: Equity, reserves, BVPS — AR FY2025-26. Cash/investment, inventory, receivable, PP&E lines — stockanalysis.com (derived from company filings; converted from INR millions). Discrepancy: BOB Capital Markets cites "cash and bank balance" of ₹2,250 Cr in FY2026 (vs ₹1,630 Cr FY2025), a narrower definition that excludes certain deposits/investments; stockanalysis classifies ₹2,178 Cr as long-term investments. Readers should treat ₹2,250–4,410 Cr as the range depending on definition.
Lease liabilities (only "debt"): AR debt-equity ratio (lease liabilities ÷ equity) of 0.05x (FY2025) and 0.04x (FY2026) implies lease liabilities of roughly ₹212 Cr and ₹191 Cr (computed).
Working capital (FY2025–26 only): Current ratio 3.37x → 2.55x (AR). Using aggregator current assets (₹4,763 Cr FY2025; ₹3,771 Cr FY2026), implied net working capital is ≈₹3,350 Cr → ≈₹2,290 Cr (computed); the decline reflects reclassification of deposits from current to non-current, not operating deterioration.
Cash flow
Sources: OCF FY2025–26 from audited cash-flow statement (₹1,011.84 Cr; ₹1,319.24 Cr); earlier years and capex/FCF from stockanalysis.com. Discrepancies: (1) the AR KPI page shows FY2025 cash generated from operations as ₹1,024 Cr versus ₹1,011.84 Cr in the audited cash-flow statement; (2) screener.in shows FY2026 FCF of ₹1,307 Cr vs ₹1,278 Cr computed above.
Commentary. Cash conversion is structurally strong (5-year cumulative FCF ≈₹5,165 Cr vs cumulative PAT ≈₹5,915 Cr; ~87%), with capex consistently <1% of revenue. FY2025 was the weak year (OCF −17%) because inventory jumped ₹262 Cr (₹620 Cr → ₹882 Cr) and other receivables rose; FY2026 OCF recovered 30% to ₹1,319 Cr despite inventory days rising to 90.4 from 78.3. Effectively all FCF is distributed; the FY2026 ₹656 dividend implies a cash outflow of ≈₹1,394 Cr in FY2027 — above FY2026 FCF — funded from the cash pile.
Ratios
Note: AR labels PAT ÷ average capital employed as "RoCE" (29.5/31.6/34.9/35.7/34.5%); for a debt-free company this equals ROE. AR "Return on Net Worth" is 35.66% (FY2025) and 34.46% (FY2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pharmaceuticals segment revenue (INR Cr) | 5,849 | 6,409 | 6,929 |
Segment profit before tax (INR Cr) | 1,618 | 1,887 | 2,079 |
PBT margin (%) | 27.7 | 29.4 | 30.0 |
Revenue YoY growth (%) | 9.4 | 9.6 | 8.1 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Segment Revenue
| Division | Products (flagship) | FY2026 performance commentary (AR FY2025-26) | Market rank (IQVIA MAT Mar 2026) |
|---|---|---|---|
Gastrointestinal | Udiliv, Duphalac, Cremaffin/Cremaffin Plus, Digene, Creon, Ganaton, Colospa, Librax, Heptral, Vonefi, Digeraft | Robust double-digit growth, significantly ahead of market; Udiliv crossed ₹700 Cr; Ganaton became 7th GI brand above ₹100 Cr | #4 in GI; #1 in hepatoprotectives |
Metabolics | Thyronorm, Combinorm Plus, Extensior; distributed Novo insulins/Rybelsus/Awiqli | Thyronorm sustained leadership; Extensior marked GLP-1 entry | #1 in hormones |
Women's Health | Duphaston, Femoston, Duvadilan, Femilon, Novelon | Resilient despite dydrogesterone generic price pressure; diversification into fertility, contraception, menopause | #4 in gynaecology |
CNS | Vertin, Prothiaden, Inderal, Zolfresh | Consistent growth led by Vertin in vertigo | #4 in CNS |
Multi-Specialty | Arachitol (Nano, injection), Brufen | Strong growth led by Arachitol nano-formulation; SKU rationalisation | — |
Vaccines | Influvac, Pneumoshield 14, Havshield, typhoid and JE vaccines | Stable; trivalent/quadrivalent influenza transition intensified pricing pressure | #4 in vaccines |
“—” = not publicly disclosed.
Therapy Details
| Therapy (MAT July 2026) | Sales (INR Cr) | YoY growth (%) | Share of Abbott India secondary sales (%) |
|---|---|---|---|
Gastrointestinal | 2,300 | not stated | 46 |
Women's Health | 492 | 8 | 10 |
Total Abbott India (secondary) | 5,000 | 10 | 100 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 4,913 | 5,349 | 5,849 | 6,409 | 6,929 |
Other income (INR Cr) | 83 | 154 | 248 | 276 | 288 |
Material cost (INR Cr) | 2,657 | 2,975 | 3,220 | 3,497 | 3,693 |
Gross profit (INR Cr, computed) | 2,256 | 2,374 | 2,629 | 2,912 | 3,236 |
Employee benefit expense (INR Cr) | 579 | 564 | 577 | 588 | 669 |
Other expenses (INR Cr) | 595 | 604 | 599 | 630 | 675 |
EBITDA incl. other income (INR Cr, company definition) | 1,165 | 1,360 | 1,701 | 1,970 | 2,180 |
EBITDA excl. other income (INR Cr, computed) | 1,082 | 1,206 | 1,453 | 1,694 | 1,892 |
Depreciation & amortisation (INR Cr) | 66 | 70 | 71 | 72 | 76 |
Operating income / EBIT excl. other income (INR Cr, computed) | 1,016 | 1,136 | 1,382 | 1,622 | 1,816 |
Finance cost (INR Cr) | 19 | 16 | 12 | 11 | 25 |
Profit before tax (INR Cr) | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 |
Tax (INR Cr) | 281 | 325 | 417 | 473 | 527 |
Net income (INR Cr) | 799 | 949 | 1,201 | 1,414 | 1,552 |
EPS basic = diluted (INR) | 375.86 | 446.78 | 565.28 | 665.62 | 730.36 |
Dividend per share incl. special (INR) | 275 | 325 | 410 | 475 | 656 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth (%) | 14.0 | 8.9 | 9.4 | 9.6 | 8.1 |
Gross margin (%) | 45.9 | 44.4 | 44.9 | 45.4 | 46.7 |
EBITDA margin incl. OI (%, company) | 23.7 | 25.4 | 29.1 | 30.7 | 31.5 |
EBITDA margin excl. OI (%) | 22.0 | 22.5 | 24.8 | 26.4 | 27.3 |
Operating margin excl. OI (%) | 20.7 | 21.2 | 23.6 | 25.3 | 26.2 |
PBT margin (%) | 22.0 | 23.8 | 27.7 | 29.4 | 30.0 |
Net margin (%) | 16.3 | 17.7 | 20.5 | 22.1 | 22.4 |
Effective tax rate (%) | 26.0 | 25.5 | 25.8 | 25.1 | 25.3 |
Dividend payout (%) | 73.2 | 72.7 | 72.5 | 71.4 | 89.8 |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 1,738.35 | 1,757.15 | 1,724.04 | 1,709.51 | 1,813.68 |
Net profit (INR Cr) | 365.86 | 415.27 | 375.96 | 394.93 | 428.52 |
EPS (INR) | 172.17 | 195.42 | 176.93 | 185.85 | 201.66 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total equity (INR Cr) | 2,820 | 3,189 | 3,699 | 4,233 | 4,774 |
Share capital (INR Cr) | 21 | 21 | 21 | 21 | 21 |
Reserves & surplus (INR Cr) | 2,799 | 3,168 | 3,678 | 4,212 | 4,753 |
Book value per share (INR) | 1,327 | 1,501 | 1,741 | 1,992 | 2,247 |
Cash & cash equivalents (INR Cr) | 133 | 240 | 292 | 561 | 442 |
Current investments & bank deposits (INR Cr) | 2,603 | 1,683 | 1,826 | 2,553 | 1,790 |
Non-current deposits/investments (INR Cr) | 0 | 1,137 | 1,506 | 672 | 2,178 |
Total cash, deposits & investments (INR Cr) | 2,735 | 3,059 | 3,624 | 3,785 | 4,410 |
Bank borrowings (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net debt excl. leases (INR Cr) | -2,735 | -3,059 | -3,624 | -3,785 | -4,410 |
Inventory (INR Cr) | 688 | 649 | 620 | 882 | 947 |
Trade receivables (INR Cr) | 288 | 319 | 319 | 380 | 362 |
Property, plant & equipment incl. ROU (INR Cr) | 263 | 233 | 228 | 348 | 333 |
Goodwill (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Other intangibles (INR Cr) | 8.6 | 7.5 | 6.7 | 6.5 | 3.8 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 948 | 893 | 1,213 | 1,012 | 1,319 |
Capital expenditure (INR Cr, computed) | 44 | 34 | 48 | 53 | 41 |
Free cash flow (INR Cr) | 904 | 859 | 1,165 | 959 | 1,278 |
Dividends paid (INR Cr, computed from DPS paid in year) | 584 | 584 | 691 | 871 | 1,009 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Investing cash flow (INR Cr) | -396 | -148 | -416 | 182 | -371 |
Financing cash flow (INR Cr) | -637 | -639 | -745 | -925 | -1,066 |
FCF / net income (%) | 113 | 91 | 97 | 68 | 82 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE — PAT on average equity (%) | 29.5 | 31.6 | 34.9 | 35.7 | 34.5 |
Pre-tax return on average equity (%, computed) | 39.8 | 42.4 | 47.0 | 47.6 | 46.2 |
Debt (leases) to equity (x) | 0.0 | 0.0 | 0.0 | 0.05 | 0.04 |
Cash conversion cycle (days, screener.in) | -6 | -8 | -24 | 3 | 3 |
Working Capital (Days) and Financial Ratios (x)
| Ratio (two-year, AR FY2025-26) | FY2025 | FY2026 |
|---|---|---|
Debtor days | 19.91 | 19.54 |
Inventory days | 78.33 | 90.40 |
Interest coverage (x) | 166.09 | 84.20 |
Current ratio (x) | 3.37 | 2.55 |
Operating profit margin incl. OI, EBIT basis (%) | 29.60 | 30.37 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue from operations, all geographies (INR Cr) | 5,849 | 6,409 | 6,929 |
YoY growth (%) | 9.4 | 9.6 | 8.1 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 31 March (INR) | 17,699 | 22,087 | 26,946 | 30,731 | 25,923 |
Market capitalisation (INR Cr) | 37,610 | 46,932 | 57,258 | 65,300 | 55,085 |
Dividend per share (INR) | 275 | 325 | 410 | 475 | 656 |
EPS (INR) | 375.86 | 446.78 | 565.28 | 665.62 | 730.36 |
P/E at year-end (x, computed) | 47.1 | 49.4 | 47.7 | 46.2 | 35.5 |
Share Price & Returns
| Horizon | Return | Basis |
|---|---|---|
1 year | ≈ −12% | to 15 Oct 2026 (Kotak data) |
3 years | ≈ +14% cumulative | to 27 Aug 2026 (Anand Rathi data) |
Since 31 Mar 2022 (~4.5 years) | ≈ +48% | ₹17,699 → ₹26,170 (computed) |
10-year CAGR | 18.8% | to 31 Mar 2026 (AR) |
52-week range | ₹25,135 – ₹30,655 | as of 15 Oct 2026 |
Last close | ₹26,170 | 16 Oct 2026 |
Valuation Multiples
| Multiple | Abbott India | Basis |
|---|---|---|
P/E (TTM EPS ₹759.85) | 34.4x | FY2026 EPS + Q1 FY2027 − Q1 FY2026 |
P/B (BVPS ₹2,247) | 11.6x | March 2026 book |
EV/EBITDA (TTM EBITDA incl. OI ≈₹2,257 Cr; EV ≈₹53,360 Cr using ₹2,250 Cr cash) | ≈23.6x | Computed; ≈22.7x if ₹4,410 Cr cash/investments deducted |
EV/Sales (TTM revenue ≈₹7,004 Cr) | ≈7.6x | Computed |
Dividend yield (₹656) | ≈2.5% | Includes special dividend |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (INR) | Thesis |
|---|---|---|---|---|
BOB Capital Markets | 13 May 2026 | BUY | 36,457 | 40%+ ROCE, cash optionality; PAT CAGR moderated by Mixtard phase-out |
ICICI Securities | 13 Feb 2026 | BUY | 32,150 | 35x FY2028E EPS ₹918.4 |
ICICI Securities | 13 Aug 2026 | (BUY, per secondary report) | 32,210 | Post-Q1 update |
Unnamed brokerage | 11 May 2026 | Double downgrade | — | Weak growth outlook (headline only) |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
No numerical guidance. Management targets market-aligned growth, continued margin improvement through mix and productivity, scaling Extensior, above-market growth in GI, double-digit growth in Multi-Specialty, and expansion in adult vaccines and women's health adjacencies (AR FY2025-26, divisional outlooks for FY2026-27).
Consensus-type expectations (broker models)
ICICI Securities models revenue growth of ~9–10% and PAT growth of ~9–13% over FY2026E–FY2028E with EBITDA margins ~27–28% (excl. OI basis); BOB Capital expects EPS growth of ~10–12% annually. Q1 FY2027 delivered profit growth (+17%) ahead of these trends but revenue growth (+4.3%) below them.
Bull case
-
Mix-driven margin expansion continues. As low-margin Mixtard rolls off, own brands (gross margin already 46.7%) form a larger share; Q1 FY2027 EBITDA margin of 28.8% versus 25.6% a year earlier is evidence.
-
Two new growth vectors. Extensior and Awiqli give Abbott India exposure to the fastest-growing therapy in the IPM (anti-diabetics +17.6%), with Novo bearing development and manufacturing.
-
Capital return and optionality. ₹2,250–4,410 Cr of cash, zero debt and ~90% payout support a ~2.5% yield, with explicit appetite for in-licensing/M&A.
Bear case
-
Structural growth gap. Reported revenue grew 4.3% in Q1 FY2027 while the IPM grew ~14%; if core brands only match the market, the insulin roll-off caps top-line growth near mid-single digits for several quarters.
-
GLP-1 economics may disappoint. Extensior launched into semaglutide genericisation; pricing could compress rapidly, and Abbott is a distributor, not owner.
-
Cost reinvestment and governance flux. Employee costs rose 13.8% in FY2026; 2026 saw a new MD (2025), new Chairman, multiple board changes and a CS exit — execution risk during a portfolio transition.
Catalysts and monitorables (next 12 months)
| Item | Timing |
|---|---|
| Q2 FY2027 results (revenue growth vs IPM ~14.7% in the quarter) | By 14 Nov 2026 |
| New Company Secretary appointment | Around 28 Oct 2026 |
| Extensior and Awiqli monthly offtake (Pharmarack/IQVIA) | Monthly |
| Mixtard residual sales and final exit timing | Ongoing |
| Independent-director succession (Chairman's second ID term ends ~31 Mar 2027) | Q4 FY2027 |
| Q3 FY2027 results; IPM CY2026 exit growth | Feb 2027 |
| FY2027 results and dividend (payout level vs FY2026's ~90%) | May 2027 |
| Any in-licensing or acquisition using cash | Event-driven |
| NLEM/DPCO revisions affecting Thyronorm, Mixtard-type molecules, vaccines | Event-driven |
Analyst verdict
Abbott India remains one of the highest-quality franchises in Indian pharma on every balance-sheet and return metric: zero financial debt, roughly 35% ROE, cash conversion above 85% of earnings over five years, and dominant positions in thyroid, hepatoprotection, laxatives, antacids and vertigo. The five-year record — revenue up ~9% a year, profit up ~18% a year — is a story of disciplined operating leverage and portfolio mix rather than volume heroics.
The debate has shifted from quality to growth. FY2026 revenue rose only 8.1% and Q1 FY2027 just 4.3%, precisely when the Indian market accelerated to double digits. The proximate cause is clear and largely exogenous: Novo Nordisk's withdrawal of Human Mixtard, a top-five IPM brand distributed by Abbott India. That roll-off depresses reported sales but flatters margins, which is why profit growth (+17% in Q1) is diverging from the top line. Underlying own-brand growth of ~10% (Pharmarack MAT July 2026) appears healthy but not outstanding against a 13% market.
The 2026 partnerships — Extensior and Awiqli — show that Novo still regards Abbott India as its preferred access partner, and they offer genuine optionality in diabetes. However, Abbott's role is that of a distributor, and the GLP-1 entry coincides with semaglutide genericisation, so these are unlikely to restore double-digit growth by themselves within twelve months.
At ~34x trailing earnings and ~23x EV/EBITDA, the stock has de-rated by roughly a quarter from its historic multiple and now trades near its 52-week low with a ~2.5% yield. The Q2 FY2027 print versus a ~15% IPM quarter is the key near-term test.
Source list (principal): Abbott India Annual Report 2025-26 (abbott.co.in); Statement of Audited Financial Results, quarter and year ended 31 March 2026 (abbott.co.in); Q1 FY2027 unaudited results and board outcome (BSE, 12 Aug 2026); Abbott/Novo Nordisk Extensior press release and BSE intimation (27 Feb 2026); BSE/NSE disclosures on directors, KMP and CS (2025–26); BOB Capital Markets research (29 Apr 2025, 4 Jul 2025, 12 Feb 2026, 13 May 2026, 13 Jul 2026, 3 Sep 2026); ICICI Securities result updates (8 Nov 2025, 13 Feb 2026); Pharmarack/Equirus/PharmaTrac IPM reports (Jan–Oct 2026); Novo Nordisk India Awiqli launch coverage (Reuters via Medical Dialogues, BioSpectrum, Jul 2026); Business Standard and exchange aggregators for shareholding and prices (Oct 2026); stockanalysis.com and screener.in for balance-sheet and cash-flow line items; GSK Pharmaceuticals, Pfizer Ltd, Sanofi India and Mankind Pharma results filings/coverage (2026); Indian Pharma Post (Chairman appointment, Aug 2026); The Print/Medical Dialogues (NPPA overcharging, 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Since | Background | Notes |
|---|---|---|---|---|
Dr. Sudarshan Jain (DIN 00927487) | Chairman, Independent Director | ID since 2019; Chairman from 13 Aug 2026 | 40+ years in pharma; formerly Director-Marketing at Abbott India and GM, Healthcare Solutions at Abbott Healthcare; Secretary-General, Indian Pharmaceutical Alliance | Second ID term began 1 Apr 2022 (ends 31 Mar 2027 by five-year arithmetic) — a near-term succession item |
Kartik Rajendran (DIN 09527717) | Managing Director | 14 Jun 2025 (to 13 Jun 2030) | 20+ years; MBA, Indian School of Business; BA English Literature, Delhi University; previously Regional Head, Abbott SE Asia pharma; GM Specialty Care, Commercial Director Hospital Business, India Head New Products at Abbott Healthcare; ~6 years at McKinsey | Age reported as 47 (GlobalData) |
Kaiyomarz Marfatia (DIN 03449627) | Non-Executive Director | Long-serving (former Whole-time Director) | Abbott India veteran | — |
Shalini Kamath (DIN 06993314) | Independent Director | — | — | — |
Vivek Mohan (DIN 00075006) | Non-Executive Director | 1 Jan 2026 | — | — |
Darshan Gada (DIN 08174581) | Non-Executive Director | 18 Aug 2025 | — | — |
James Wenner (DIN 11650998) | Non-Executive Director | 23 Apr 2026 | Vice President & Treasurer, Abbott Laboratories, USA | Confirmed via postal ballot (results due by 18 Jun 2026) |
Neeraj Jain (DIN 00348591) | Independent Director | 25 Apr 2026 | Chartered accountant; 30+ years incl. Johnson & Johnson, Hindustan Unilever | Three-year term |
Board of Directors — Kartik Rajendran
| Name | Title | Notes |
|---|---|---|
Kartik Rajendran | Managing Director | See above |
Maithilee Mistry | Chief Financial Officer | KMP from 6 May 2025 |
Sangeeta Shetty | Company Secretary & Compliance Officer | Resigns effective 28 Oct 2026; successor not yet announced in sources reviewed |
Devesh Choudhari | Director, Finance | — |
Harshraj Madan | Commercial Director, Gastrointestinal | — |
Prithwish Banerji | Commercial Director, Women's Health, Metabolics & International Business | — |
Anuj Mehra | Commercial Director, CNS, Multi-Specialty & Vaccines | — |
Dr. Jejoe Karankumar | Director, Medical Affairs | — |
Vinutha Mufti | Director, Business HR | From 16 Dec 2025 |
Anushree Kunhambu | Associate Director, New Product Introduction & Therapy Strategy | From 1 Aug 2025 |
Richa Tripathi | Associate Director, Sales Force Effectiveness & PMO | — |
Amol Metkar | Plant Director, Goa | From 1 Jun 2026; ex-Lupin, Sanofi, Cipla, Ranbaxy |
Major Shareholders
| Holder category | Stake (%) |
|---|---|
Promoter group (Abbott Laboratories entities) | 74.99 |
UTI Mutual Fund (schemes) | 7.55 |
Insurance companies | 1.25 |
Foreign institutional investors | 0.40 |
Non-institutional investors | 2.44 |
Indian public (individuals) | 13.19 |
Competitive Landscape
Competitor Detail
| Therapy | Key competitors (named) | Abbott positioning |
|---|---|---|
Gastrointestinal | Sun Pharma, Alkem (Pan, Pan-D), Torrent, Dr. Reddy's, Mankind, Zydus, Cipla | #4 in GI; #1 hepatoprotectives (Udiliv); leadership in laxatives, antacids, enzymes, prokinetics |
Thyroid / Hormones | Merck/Macleods (Thyrox), GSK (Eltroxin), Mankind, Intas | #1 (Thyronorm, ~56% share) |
Diabetes / GLP-1 / insulin | Novo Nordisk (direct), Eli Lilly (Mounjaro; Cipla partnership), Sanofi (Lantus, Toujeo, Soliqua), USV (Glycomet), Emcure (Poviztra, Wegovy second brand), Natco/Eris, Biocon, Lupin, Dr. Reddy's (semaglutide generics) | Distributor of Novo brands; new GLP-1 entrant via Extensior |
Women's Health | Sun Pharma, Mankind, Zydus, Intas, Lupin, generic dydrogesterone players | #4 in gynaecology; Duphaston leader in dydrogesterone |
CNS | Sun Pharma, Torrent, Intas, Lupin, Cipla (vertigo: Stugeron-class/betahistine generics) | #4 in CNS; Vertin leader in vertigo |
Vaccines | Sanofi, GSK, Serum Institute, Zydus, Bharat Biotech, MSD, Pfizer | #4 in vaccines; Influvac key adult flu brand |
Multi-Specialty | Mankind, Alkem, Sun, Cadila (vitamin D: Calcirol etc.) | Arachitol nano differentiation |
Peer Comparison FY2026
| Metric | Abbott India | GSK Pharmaceuticals (India) | Pfizer Ltd (India) | Mankind Pharma |
|---|---|---|---|---|
Fiscal year | FY2026 (Mar) | FY2026 (Mar), consolidated | FY2026 (Mar) | FY2026 (Mar), consolidated |
Revenue (INR Cr) | 6,929 | 3,822 | 2,520 | 14,278 |
Revenue growth (%) | 8.1 | 1.9 | 10.4 | 17.0 |
EBITDA/OPM margin (%) | 27.3 (excl. OI) | 34.3 | 35.9 (computed, operating profit ₹904 Cr) | 25.4 (adjusted) |
Net profit (INR Cr) | 1,552 | 1,036 | 722 | ≈1913 (computed at 13.4% margin) |
Net margin (%) | 22.4 | 27.1 | 28.7 | 13.4 |
R&D intensity | Not disclosed (minimal) | Not disclosed (minimal) | Not disclosed (minimal) | — |
Dividend per share FY2026 (INR) | 656 | 57 | 75 | — |



